The data were presented by John Leonard, M.D. in an oral presentation at the 60th American Society of Hematology annual meeting and Exposition in San Diego, C.A.
The phase 3 randomised, double-blind, international clinical study evaluated the efficacy and safety of the investigational combination of R2 versus rituximab plus placebo in patients (n=358) with relapsed/refractory follicular (n=295) and marginal zone lymphoma.
In the study, the R2 arm demonstrated a highly statistically significant improvement in the primary endpoint of progression-free survival, evaluated by an independent review committee, versus the R-placebo arm.
The median PFS was 39.4 months for patients treated with R2 and 14.1 months for those treated with R-placebo (P
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval